Search Results
David S. Rosenbloom
David S. Rosenbloom is executive vice president and general counsel. Rosenbloom joined Baxter in 2022 from McDermott Will & Emery, where he served as a partner for 24 years and global head of the Litigation Practice Group from 2017-2022. Prior to McDermott, he served for eight years in the U.S. Attorney’s Office for the Northern District of Illinois.
Gerard (Jerry) Greco, Ph.D.
Gerard (Jerry) Greco, Ph.D., is senior vice president, chief quality officer. Greco joined Baxter in 2023 from Takeda Pharmaceuticals, where he most recently served as the global quality officer, leading all quality and quality compliance for the company. During his 35-plus years in the healthcare industry, he has served in quality roles of increasing responsibility at Teva Pharmaceuticals, Pfizer, Wyeth Pharmaceuticals and Johnson & Johnson.
Olimel Portfolio
The Olimel portfolio consists of eight unique olive oil-based parenteral (intravenous) nutrition formulations designed to match the personalized protein and energy needs of patients.
Doxil (doxorubicin HCl liposome injection) for Hospital Care
Doxil (doxorubicin HCl liposome injection) is indicated for treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.
Tobi Karchmer, M.D., M.S.
Tobi Karchmer, M.D., M.S., is senior vice president and chief medical and scientific officer. Prior to her appointment to chief medical officer in 2021, Karchmer served as vice president, Worldwide Medical, which consists of Baxter's Global and Regional Medical Affairs teams, Clinical Research team and Strategy and Delivery team.